Clinical trials: Pregabalin
Partial Seizures, Epilepsies, Partial
Once-A-Day Pregabalin For Partial Seizures
Approximately 30% percent of subjects with partial seizures are refractory to treatment with single or combination antiepileptic drugs.
- Trial name
- NCT01262677
- Testing
- pregabalin
- Where
- 82 sites in United States, Argentina and 16 more
- Volunteers
- 325 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Post Herpetic Neuralgia
Safety And Efficacy Study Of Once Daily Controlled Release Pregabalin In The Treatment Of Patients With Postherpetic Neuralgia
The purpose of the study is to explore the safety and efficacy of a new once a day pregabalin formulation versus placebo for patients with post herpetic neuralgia (Shingles)
- Trial name
- NCT01270828
- Testing
- Pregabalin
- Where
- 146 sites in United States, Bulgaria and 15 more
- Volunteers
- 806 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Anxiety Neuroses
Determine Long-Term Safety and Tolerability of Pregabalin in Patients With Anxiety Disorders.
Determine long-term safety and tolerability of pregabalin in patients with anxiety disorders.
- Trial name
- NCT00150449
- Testing
- Pregabalin
- Where
- 138 sites in Austria, Belgium and 12 more
- Volunteers
- 511 people
- Sponsor
- Pfizer
Fibromyalgia
Study Of A Controlled Release Formulation Of Pregabalin In Fibromyalgia Patients
The purpose of this study is to evaluate the efficacy and safety of a controlled release formulation of pregabalin administered once daily as compared to placebo in the treatment of fibromyalgia.
- Trial name
- NCT01271933
- Testing
- pregabalin
- Where
- 52 sites in United States, Canada and 2 more
- Volunteers
- 441 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Healthy
An Investigation Of The Absorption And Pharmacokinetics Of Multiple Doses Of Two Controlled Release Pregabalin Tablets As Compared To Multiple Doses Of The Immediate Release Pregabalin Capsule In Healthy Volunteers
The purpose of this study is to 1) evaluate the extent of absorption of multiple doses of two pregabalin controlled release tablets as compared to multiple doses of the pregabalin immediate release capsule, 2) evaluate the…
- Trial name
- NCT01220219
- Testing
- Pregabalin controlled release, 82.5 mg, Pregabalin controlled release, 165 mg, Pregabalin immediate release, 75mg
- Where
- Belgium
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Diabetic Neuropathy, Painful
A Study To Evaluate Pregabalin In Patients With Painful Diabetic Peripheral Neuropathy (DPN)
A study of pregabalin efficacy and safety in a racially and culturally diverse group of subjects with painful diabetic peripheral neuropathy (DPN).
- Trial name
- NCT00156078
- Testing
- pregabalin
- Where
- 35 sites in Argentina, Brazil and 17 more
- Volunteers
- 450 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Seizures
Pregabalin In Partial Seizures: An Open-Label, International, Multicenter Add-On Therapy Trial.
To assess the clinical improvement (change in seizure frequency), safety and tolerability of patients with partial seizures following adjunctive therapy of pregabalin BID in addition to existing standard AEDs.
- Trial name
- NCT00141427
- Testing
- Pregabalin
- Where
- 57 sites in Belgium, Finland and 6 more
- Volunteers
- 540 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Pain, Diabetic Peripheral Neuropathy
Asian Phase 2 Study for Treatment of Pain Associated With Diabetic Peripheral Neuropathy
The purpose of this study is to investigate the effectiveness and safety of DS-5565, compared to placebo, in subjects with pain associated with diabetic peripheral neuropathy.
- Trial name
- NCT01504412
- Testing
- DS-5565, Pregabalin capsules
- Where
- 3 sites in Japan, South Korea and 1 more
- Volunteers
- 450 people
- Sponsor
- Daiichi Sankyo Co., Ltd.
Spinal Cord Injuries
Study to Determine if a Reduction in Pain Can be Measured in Spinal Cord Injured Patients Using a New Study Design
The study is designed to assess if spinal cord injury patients have reduced pain after taking either pregabalin or placebo in a cross over design.
- Trial name
- NCT00978341
- Testing
- Pregabalin
- Where
- 4 sites in Australia
- Volunteers
- 15 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Post-Herpetic Neuralgia
Study of Pregabalin Therapy for Pain Relief in Subjects With Post-Herpetic Neuralgia
The purpose of this study is to measure how rapidly pregabalin treatment can relieve pain in patients with post-herpetic neuralgia
- Trial name
- NCT00159666
- Testing
- pregabalin
- Where
- 40 sites in United States, Germany and 3 more
- Volunteers
- 255 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Fibromyalgia
A Phase 3b Multicenter Study of Pregabalin in Fibromyalgia Subjects Who Have Comorbid Depression
The intent of this study is to identify and treat fibromyalgia subjects with comorbid depression who are receiving an SSRI (selective serotonin reuptake inhibitor) or SNRI (selective norepinephrine reuptake inhibitor) primarily…
- Trial name
- NCT01432236
- Testing
- Pregabalin
- Where
- 37 sites in United States, Canada and 2 more
- Volunteers
- 197 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Epilepsies, Partial, Epilepsy, Complex Partial
Pregabalin Open-Label Extension Trial in Patients With Partial Seizures
The primary purpose of the protocol is to evaluate the long-term safety of pregabalin in patients with partial seizures.
- Trial name
- NCT00143143
- Testing
- Pregabalin
- Where
- 47 sites in Austria, Canada and 6 more
- Volunteers
- 300 people
- Sponsor
- Pfizer
Neuropathic Pain
Study To Assess The Reproducibility And Sensitivity Of Quantitative Sensory Testing In Patients With Neuropathic Pain
Conventional pain efficacy measures such as Visual Analogue Scores (VAS) are often unable to detect treatment efficacy in small-scale clinical trials.
- Trial name
- NCT01117766
- Testing
- Pregabalin
- Where
- 5 sites in Austria, Belgium and 2 more
- Volunteers
- 31 people
- Sponsor
- Pfizer
Healthy
An Investigation of the Absorption and Pharmacokinetics of Multiple Doses of Three Controlled Release Pregabalin Tablets as Compared to Multiple Doses of the Immediate Release Pregabalin Capsule
The purpose of this study is to 1) evaluate the extent of absorption of multiple doses of three pregabalin controlled release tablets as compared to multiple doses of the pregabalin immediate release capsule, 2) evaluate the…
- Trial name
- NCT01009541
- Testing
- Pregabalin controlled release, 82.5 mg, Pregabalin controlled release, 165 mg, Pregabalin controlled release, 330 mg
- Where
- Belgium
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Diabetic Neuropathy, Painful
To Evaluate the Safety and Efficacy of Pregabalin in Patients With Painful Diabetic Peripheral Neuropathy.
To evaluate the safety and efficacy of pregabalin in patients with painful diabetic peripheral neuropathy.
- Trial name
- NCT00150423
- Testing
- Pregabalin
- Volunteers
- 384 people
- Sponsor
- Pfizer
Healthy
Assessment of the Analgesic Effects of PF-05089771 and Pregabalin in Healthy Volunteers Using Evoked Pain Endpoints
This study will examine the activity of PF-05089771 and pregabalin, alone and in combination on a panel of evoked pain tests carried out from 0.5 to 10 hours following oral dosing in healthy male subjects
- Trial name
- NCT02349607
- Testing
- PF-05089771 300mg, PF-05089771 300 mg + pregabalin 300 mg, pregabalin 300 mg
- Where
- Netherlands
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Pfizer
Diabetic Neuropathy, Painful
A Study in Painful Diabetic Neuropathy
This study will investigate the efficacy of a combination treatment of duloxetine + pregabalin compared with the maximal dose of each drug in monotherapy, in patients with diabetic peripheral neuropathic pain (DPNP) who have not…
- Trial name
- COMBO-DN (NCT01089556)
- Testing
- Duloxetine, Pregabalin
- Where
- 54 sites in Australia, Canada and 14 more
- Volunteers
- 811 people
- Sponsor
- Eli Lilly and Company
Healthy Male and Female Subjects
Pharmacokinetics of Y-4 Tablets With Pregabalin Capsules and Riluzole Tablets in U.S. Healthy Participants
The primary goal of this clinical trial is to compare pharmacokinetic characteristics of Y-4 tablets with pregabalin capsules and riluzole tablets in the US healthy adult participants after single oral administration under fasted…
- Trial name
- NCT07618715
- Testing
- Y-4 tablet, Pregabalin capsule, Riluzole tablet
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- Neurodawn Pharmaceutical Co., Ltd.
Diabetic Peripheral Neuropathic Pain
A Study of Duloxetine (LY248686) in Participants With Diabetic Peripheral Neuropathic Pain (DPNP)
The main purpose of this study is to evaluate the effectiveness and safety of the study drug known as duloxetine in participants with diabetic peripheral neuropathic pain.
- Trial name
- NCT02417935
- Testing
- Duloxetine, Pregabalin
- Volunteers
- 304 people
- Sponsor
- Eli Lilly and Company
Low Back Pain, Neuropathic Pain
Comparison of Increasing Doses of Tapentadol Versus a Combination of Tapentadol and Pregabalin
The main objective of the study is to evaluate the effectiveness, safety, and tolerability of increasing doses of tapentadol prolonged release (PR) (500 mg per day) versus a combination of tapentadol PR (300 mg per day) and…
- Trial name
- NCT01352741
- Testing
- Tapentadol Prolonged Release, Tapentadol Prolonged Release with Pregabalin, Tapentadol Prolonged Release open label maintenance
- Where
- 59 sites in Austria, Belgium and 5 more
- Volunteers
- 622 people
- Sponsor
- Grünenthal GmbH